Emerald Mutual Fund Advisers Trust’s Catalyst Pharmaceutical CPRX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,083,284	Closed	-$5.75M	–	290
2019 Q3	$5.75M	Buy	+1,083,284	New	+$5.77M	0.25%	120
2018 Q2	–	Sell	-938,078	Closed	-$2.24M	–	239
2018 Q1	$2.24M	Buy	938,078 +231,328	+33%	+$769K	0.09%	195
2017 Q4	$2.76M	Buy	+706,750	New	+$2.33M	0.11%	185
2015 Q2	–	Sell	-150,000	Closed	-$533K	–	259
2015 Q1	$533K	Buy	+150,000	New	+$541K	0.04%	192

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CPRX Position: Q4 2019 in Review

Emerald Mutual Fund Advisers Trust sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 1,083,284 shares — an estimated $5.75M sold.

Emerald Mutual Fund Advisers Trust first reported a position in CPRX in Q1 2015 and held it in 4 quarters. The position peaked at $5.75M in Q3 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

Emerald Mutual Fund Advisers Trust reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 1,083,284 Catalyst Pharmaceutical shares in Q4 2019, an estimated $5.75M.
Emerald Mutual Fund Advisers Trust first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 4 quarters.
Emerald Mutual Fund Advisers Trust's Catalyst Pharmaceutical position peaked at $5.75M in Q3 2019.
130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2019, filed 29 Jan 2020.